Augustine Odili, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypertension | 29 | 2024 | 8616 | 2.890 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 9 | 2023 | 254 | 2.420 |
Why?
|
Nigeria | 19 | 2023 | 782 | 2.360 |
Why?
|
Blood Pressure | 25 | 2023 | 8530 | 1.970 |
Why?
|
Blood Pressure Determination | 6 | 2023 | 646 | 1.110 |
Why?
|
Antihypertensive Agents | 8 | 2024 | 2028 | 1.050 |
Why?
|
Hypertrophy, Left Ventricular | 2 | 2019 | 855 | 0.840 |
Why?
|
Hyperhomocysteinemia | 1 | 2021 | 117 | 0.700 |
Why?
|
Rural Population | 3 | 2022 | 2318 | 0.640 |
Why?
|
Homocysteine | 1 | 2021 | 638 | 0.580 |
Why?
|
Dyslipidemias | 2 | 2021 | 871 | 0.560 |
Why?
|
Quality Control | 2 | 2019 | 835 | 0.550 |
Why?
|
Hyperlipidemias | 1 | 2021 | 770 | 0.540 |
Why?
|
Sodium | 1 | 2021 | 1591 | 0.520 |
Why?
|
Awareness | 1 | 2020 | 653 | 0.510 |
Why?
|
Bisoprolol | 2 | 2012 | 9 | 0.500 |
Why?
|
Electrocardiography | 2 | 2019 | 6409 | 0.480 |
Why?
|
Amlodipine | 2 | 2012 | 84 | 0.480 |
Why?
|
Hydrochlorothiazide | 2 | 2012 | 95 | 0.480 |
Why?
|
Hypercholesterolemia | 1 | 2021 | 1148 | 0.470 |
Why?
|
Qualitative Research | 2 | 2024 | 3136 | 0.450 |
Why?
|
Africa | 3 | 2024 | 725 | 0.440 |
Why?
|
Office Visits | 1 | 2017 | 594 | 0.430 |
Why?
|
Rural Health | 1 | 2015 | 301 | 0.420 |
Why?
|
Belgium | 4 | 2022 | 119 | 0.410 |
Why?
|
Prevalence | 9 | 2024 | 15828 | 0.400 |
Why?
|
Self Care | 1 | 2017 | 800 | 0.390 |
Why?
|
Population Surveillance | 2 | 2020 | 2596 | 0.350 |
Why?
|
Anthropometry | 1 | 2015 | 1339 | 0.340 |
Why?
|
Sphygmomanometers | 2 | 2022 | 20 | 0.330 |
Why?
|
Disease Management | 1 | 2020 | 2530 | 0.330 |
Why?
|
Tetrazoles | 2 | 2012 | 918 | 0.320 |
Why?
|
Marfan Syndrome | 1 | 2011 | 237 | 0.310 |
Why?
|
Life Style | 2 | 2022 | 3928 | 0.300 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7423 | 0.280 |
Why?
|
Periodontal Diseases | 1 | 2010 | 453 | 0.280 |
Why?
|
Aortic Valve Insufficiency | 1 | 2011 | 575 | 0.270 |
Why?
|
Cardiovascular Diseases | 7 | 2024 | 15645 | 0.260 |
Why?
|
Aortic Aneurysm | 1 | 2011 | 649 | 0.260 |
Why?
|
Physicians | 1 | 2023 | 4591 | 0.250 |
Why?
|
Primary Health Care | 1 | 2022 | 4736 | 0.240 |
Why?
|
Blood Glucose | 2 | 2022 | 6422 | 0.240 |
Why?
|
Adult | 23 | 2024 | 223088 | 0.230 |
Why?
|
Middle Aged | 26 | 2024 | 223016 | 0.230 |
Why?
|
Cholesterol, HDL | 2 | 2021 | 1813 | 0.230 |
Why?
|
Africa South of the Sahara | 4 | 2024 | 751 | 0.230 |
Why?
|
Quality Assurance, Health Care | 1 | 2014 | 2170 | 0.220 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 1513 | 0.220 |
Why?
|
Humans | 45 | 2024 | 765926 | 0.220 |
Why?
|
Male | 27 | 2024 | 363815 | 0.200 |
Why?
|
Stethoscopes | 1 | 2022 | 30 | 0.190 |
Why?
|
Drugs, Essential | 1 | 2022 | 71 | 0.180 |
Why?
|
Risk Factors | 12 | 2024 | 74850 | 0.180 |
Why?
|
Delphi Technique | 1 | 2024 | 893 | 0.170 |
Why?
|
Female | 28 | 2024 | 396141 | 0.170 |
Why?
|
Health Personnel | 2 | 2024 | 3385 | 0.170 |
Why?
|
Hyperinsulinism | 1 | 2023 | 402 | 0.170 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 26282 | 0.160 |
Why?
|
Ankle Brachial Index | 1 | 2019 | 164 | 0.150 |
Why?
|
Diuretics | 2 | 2012 | 611 | 0.150 |
Why?
|
Sodium Chloride, Dietary | 1 | 2020 | 303 | 0.150 |
Why?
|
Rural Health Services | 1 | 2022 | 393 | 0.150 |
Why?
|
Self-Help Groups | 1 | 2019 | 194 | 0.150 |
Why?
|
Potassium | 1 | 2021 | 1312 | 0.140 |
Why?
|
Demography | 1 | 2022 | 1640 | 0.140 |
Why?
|
Perception | 1 | 2023 | 1204 | 0.140 |
Why?
|
Health Facilities | 1 | 2022 | 577 | 0.140 |
Why?
|
Research Design | 2 | 2019 | 6204 | 0.130 |
Why?
|
Aged | 13 | 2024 | 171163 | 0.130 |
Why?
|
Cognition Disorders | 1 | 2010 | 3965 | 0.130 |
Why?
|
Program Evaluation | 1 | 2024 | 2502 | 0.130 |
Why?
|
Drug Combinations | 2 | 2012 | 2075 | 0.120 |
Why?
|
Oscillometry | 1 | 2015 | 151 | 0.120 |
Why?
|
Risk Assessment | 6 | 2021 | 24275 | 0.120 |
Why?
|
Cadmium | 1 | 2015 | 218 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2023 | 1389 | 0.110 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12059 | 0.110 |
Why?
|
Sampling Studies | 1 | 2015 | 610 | 0.110 |
Why?
|
Nephrolithiasis | 1 | 2015 | 117 | 0.110 |
Why?
|
Triglycerides | 1 | 2021 | 2440 | 0.110 |
Why?
|
Sex Distribution | 2 | 2016 | 2269 | 0.110 |
Why?
|
Automation | 1 | 2015 | 585 | 0.100 |
Why?
|
Age Distribution | 2 | 2016 | 2864 | 0.100 |
Why?
|
Cholesterol | 1 | 2021 | 2902 | 0.100 |
Why?
|
Cholesterol, LDL | 1 | 2021 | 2395 | 0.100 |
Why?
|
Tablets | 1 | 2012 | 149 | 0.100 |
Why?
|
Methyldopa | 1 | 2011 | 18 | 0.090 |
Why?
|
Reference Values | 2 | 2016 | 4909 | 0.090 |
Why?
|
Hydralazine | 1 | 2011 | 34 | 0.090 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3430 | 0.090 |
Why?
|
Medication Adherence | 2 | 2022 | 2190 | 0.090 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2024 | 2307 | 0.090 |
Why?
|
Waist Circumference | 1 | 2015 | 934 | 0.090 |
Why?
|
Pre-Eclampsia | 1 | 2020 | 1257 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2022 | 1878 | 0.080 |
Why?
|
Patient Dropouts | 1 | 2012 | 411 | 0.080 |
Why?
|
Dementia, Vascular | 1 | 2010 | 126 | 0.080 |
Why?
|
Lead | 1 | 2015 | 878 | 0.080 |
Why?
|
Valine | 1 | 2011 | 410 | 0.080 |
Why?
|
Health Expenditures | 1 | 2022 | 2388 | 0.080 |
Why?
|
Feasibility Studies | 2 | 2022 | 5300 | 0.080 |
Why?
|
Adolescent | 5 | 2023 | 88811 | 0.080 |
Why?
|
Insulin Resistance | 1 | 2023 | 3988 | 0.080 |
Why?
|
Developing Countries | 2 | 2024 | 2913 | 0.080 |
Why?
|
Young Adult | 7 | 2023 | 59857 | 0.070 |
Why?
|
Linear Models | 1 | 2017 | 5873 | 0.070 |
Why?
|
Urban Population | 1 | 2015 | 2040 | 0.070 |
Why?
|
Equipment Design | 1 | 2015 | 3490 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 10380 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2022 | 3407 | 0.060 |
Why?
|
Environmental Pollutants | 1 | 2015 | 1294 | 0.060 |
Why?
|
Odds Ratio | 1 | 2017 | 9656 | 0.060 |
Why?
|
Health Surveys | 1 | 2015 | 4058 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5509 | 0.060 |
Why?
|
Administration, Oral | 1 | 2012 | 4016 | 0.060 |
Why?
|
Heart Defects, Congenital | 1 | 2020 | 4712 | 0.050 |
Why?
|
Health Care Reform | 2 | 2023 | 1257 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2015 | 59496 | 0.050 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2013 | 2136 | 0.050 |
Why?
|
Hypertension, Pulmonary | 1 | 2013 | 1604 | 0.050 |
Why?
|
Heart Rate | 1 | 2013 | 4203 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2015 | 39228 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2017 | 15401 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15878 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2015 | 4544 | 0.040 |
Why?
|
Patient Selection | 1 | 2012 | 4248 | 0.040 |
Why?
|
Research Report | 1 | 2023 | 367 | 0.040 |
Why?
|
Stroke Volume | 1 | 2013 | 5595 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 12235 | 0.040 |
Why?
|
Proteomics | 2 | 2023 | 3906 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2016 | 22228 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3430 | 0.040 |
Why?
|
Ultrasonography | 1 | 2011 | 5987 | 0.040 |
Why?
|
Pilot Projects | 2 | 2022 | 8724 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 2019 | 1607 | 0.030 |
Why?
|
Body Mass Index | 1 | 2015 | 13042 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2010 | 12417 | 0.030 |
Why?
|
Income | 1 | 2023 | 1874 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1729 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8721 | 0.030 |
Why?
|
Focus Groups | 1 | 2019 | 1458 | 0.030 |
Why?
|
Heart Failure, Diastolic | 1 | 2013 | 77 | 0.030 |
Why?
|
Heart Failure, Systolic | 1 | 2013 | 135 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2019 | 2740 | 0.020 |
Why?
|
Glucose | 1 | 2023 | 4335 | 0.020 |
Why?
|
Prospective Studies | 1 | 2015 | 54807 | 0.020 |
Why?
|
Time Factors | 1 | 2012 | 40097 | 0.020 |
Why?
|
Echocardiography, Doppler | 1 | 2013 | 899 | 0.020 |
Why?
|
China | 1 | 2015 | 2383 | 0.020 |
Why?
|
Insulin | 1 | 2023 | 6603 | 0.020 |
Why?
|
Incidence | 2 | 2015 | 21513 | 0.020 |
Why?
|
HIV Infections | 1 | 2013 | 17531 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2012 | 1238 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14745 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2012 | 65194 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3928 | 0.020 |
Why?
|
Cerebrovascular Disorders | 1 | 2010 | 1475 | 0.010 |
Why?
|
Prognosis | 2 | 2015 | 29890 | 0.010 |
Why?
|
Survival Analysis | 1 | 2013 | 10086 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14643 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2020 | 26380 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10575 | 0.010 |
Why?
|
Survival Rate | 1 | 2012 | 12822 | 0.010 |
Why?
|
Pregnancy | 1 | 2020 | 30230 | 0.010 |
Why?
|
Infant | 1 | 2020 | 36426 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13614 | 0.010 |
Why?
|
Child | 1 | 2023 | 80568 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 41680 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2015 | 81537 | 0.000 |
Why?
|